79 related articles for article (PubMed ID: 8645448)
1. Controlling IGF-receptor function: a possible strategy for tumor therapy.
Baserga R
Trends Biotechnol; 1996 May; 14(5):150-2. PubMed ID: 8645448
[TBL] [Abstract][Full Text] [Related]
2. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
[TBL] [Abstract][Full Text] [Related]
3. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
[TBL] [Abstract][Full Text] [Related]
4. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
6. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
Surmacz E
Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
8. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor I receptor: a key to tumor growth?
Baserga R
Cancer Res; 1995 Jan; 55(2):249-52. PubMed ID: 7812953
[TBL] [Abstract][Full Text] [Related]
10. The contradictions of the insulin-like growth factor 1 receptor.
Baserga R
Oncogene; 2000 Nov; 19(49):5574-81. PubMed ID: 11114737
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.
Rubin R; Baserga R
Lab Invest; 1995 Sep; 73(3):311-31. PubMed ID: 7564264
[TBL] [Abstract][Full Text] [Related]
12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
13. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
14. The IGF-I receptor in cancer research.
Baserga R
Exp Cell Res; 1999 Nov; 253(1):1-6. PubMed ID: 10579905
[TBL] [Abstract][Full Text] [Related]
15. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
16. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
Lee CT; Park KH; Adachi Y; Seol JY; Yoo CG; Kim YW; Han SK; Shim YS; Coffee K; Dikov MM; Carbone DP
Cancer Gene Ther; 2003 Jan; 10(1):57-63. PubMed ID: 12489029
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action.
Werner H; Maor S
Trends Endocrinol Metab; 2006 Aug; 17(6):236-42. PubMed ID: 16815029
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
Alexia C; Fallot G; Lasfer M; Schweizer-Groyer G; Groyer A
Biochem Pharmacol; 2004 Sep; 68(6):1003-15. PubMed ID: 15313394
[TBL] [Abstract][Full Text] [Related]
19. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]